Cureus review weighs de-escalating sleep apnoea therapy after GLP-1 weight loss
The narrative review addresses when CPAP and other obstructive sleep apnoea treatments might be stepped down in patients who lose weight on incretin drugs.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 17 11:50 ETSource: Cureus
The wire
- 01A narrative review in Cureus examines de-escalating obstructive sleep apnoea therapy after weight loss induced by GLP-1 receptor agonists.
- 02Clinicians managing patients on semaglutide or tirzepatide increasingly face questions about retitrating or stopping CPAP as weight and symptoms change.
- 03It is a narrative review rather than new trial data, so any de-escalation guidance rests on existing literature and requires repeat sleep testing.
From the source
Read at cureus.comDe-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review